This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomeAboutAboutStorage and handlingVial sizes and NDC numbersVolume illustrationsEfficacyEfficacyPivotal and extension study design and endpointsPivotal study efficacy dataExtension study efficacy dataSafety and TolerabilitySafety and
TolerabilityAdverse reactions: pivotal and extension studiesInfusion-site reactions: pivotal and extension studiesDosing and AdministrationDosing and
AdministrationFlexible infusion schedule options and infusion volume ratesInfusion duration examples (adult)Infusion duration examples (pediatric)Dosing calculatorSupportSupportMaterialsVideosPfizer IGuideTMPfizer cutaquig co-pay programIg Companion mobile app Request a representative

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-CQG-USA-0667
You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. PP-MCL-USA-0367

​​​​​​​
INDICATIONS AND USAGE

CUTAQUIG (Immune Globulin Subcutaneous [Human] - hipp) is a 16.5% immune globulin solution for subcutaneous infusion (IGSC), indicated as replacement therapy for primary humoral immunodeficiency (PI) in adults and pediatric patients 2 years of age and older. This includes, but is not limited to, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

Please see Full Prescribing Information, including BOXED WARNING and Patient Information and Instructions for Use.